RANZCP homepage
Jane Alty
Profile
Associate Professor Jane Alty
Jane is from the UK and qualified in Medicine from the University of Cambridge, UK. She completed 4 years of medical training in Cambridge, Manchester, London and Leeds and, after passing her professional postgraduate physician exams (MRCP), she undertook 5 years of specialist neurology training in Leeds and York. She completed a 6-month Movement Disorders Fellowship at Monash Medical Centre in 2007 and also took time out of her clinical neurology training to complete a 2-year period of AI-neuroscience research in Parkinson’s at the University of York; she was subsequently conferred a Doctorate of Medicine for her thesis on “Objective evaluation of Parkinson’s disease bradykinesia”. Her research made significant contributions to the commercialization of 3 medical devices (that have since been used in phase 3 clinical trials and also in clinical monitoring) and Jane was appointed as Medical Advisor of the subsequent spin out company, ClearSky Medical Diagnostics.
She was appointed Consultant Neurologist at the Leeds Teaching Hospital NHS Trust in 2013 and led specialist clinics in complex Parkinson’s disease, tremor, functional movement disorders and dystonia, including administering botulinum toxin injections and referral for advanced therapies such as deep brain stimulation surgery. She was local PI for several clinical trials in Parkinson’s disease and related disorders. In her clinical roles., Jane won a number of prizes for quality improvement projects, Clinical Excellence Awards, innovation for new devices and also national patient safety awards.
In 2019, Jane was actively recruited to UTAS as an academic neurologist. She is now the Co-Director of the UTAS ISLAND Cognitive Clinic, a one-stop interdisciplinary research cognitive clinic that provides a State-wide diagnostic service for adults with cognitive symptoms in Tasmania. She also runs a specialist Parkinson’s disease and movement disorders clinic at the Royal Hobart Hospital. She is a member of the Steering Committee for The ISLAND Project - the largest dementia prevention study in the world with >14,000 participants. In 2020, she was awarded a 5-year NHMRC Idea grant (2021-25) to develop new digital biomarkers of pre-clinical Alzheimer’s disease and now leads the TAS Test project, working with an interdisciplinary group of researchers in neuroscience, computer science and psychology. She was also awarded a 3 year Major Project Grant by the Royal Hobart Hospital Research Foundation (2022-24) and leads a team of researchers and clinicians to develop a mobile phone TapTalkTest for quick cognitive screening in clinical and research settings.
Jane is from the UK and qualified in Medicine from the University of Cambridge, UK. She completed 4 years of medical training in Cambridge, Manchester, London and Leeds and, after passing her professional postgraduate physician exams (MRCP), she undertook 5 years of specialist neurology training in Leeds and York. She completed a 6-month Movement Disorders Fellowship at Monash Medical Centre in 2007 and also took time out of her clinical neurology training to complete a 2-year period of AI-neuroscience research in Parkinson’s at the University of York; she was subsequently conferred a Doctorate of Medicine for her thesis on “Objective evaluation of Parkinson’s disease bradykinesia”. Her research made significant contributions to the commercialization of 3 medical devices (that have since been used in phase 3 clinical trials and also in clinical monitoring) and Jane was appointed as Medical Advisor of the subsequent spin out company, ClearSky Medical Diagnostics.
She was appointed Consultant Neurologist at the Leeds Teaching Hospital NHS Trust in 2013 and led specialist clinics in complex Parkinson’s disease, tremor, functional movement disorders and dystonia, including administering botulinum toxin injections and referral for advanced therapies such as deep brain stimulation surgery. She was local PI for several clinical trials in Parkinson’s disease and related disorders. In her clinical roles., Jane won a number of prizes for quality improvement projects, Clinical Excellence Awards, innovation for new devices and also national patient safety awards.
In 2019, Jane was actively recruited to UTAS as an academic neurologist. She is now the Co-Director of the UTAS ISLAND Cognitive Clinic, a one-stop interdisciplinary research cognitive clinic that provides a State-wide diagnostic service for adults with cognitive symptoms in Tasmania. She also runs a specialist Parkinson’s disease and movement disorders clinic at the Royal Hobart Hospital. She is a member of the Steering Committee for The ISLAND Project - the largest dementia prevention study in the world with >14,000 participants. In 2020, she was awarded a 5-year NHMRC Idea grant (2021-25) to develop new digital biomarkers of pre-clinical Alzheimer’s disease and now leads the TAS Test project, working with an interdisciplinary group of researchers in neuroscience, computer science and psychology. She was also awarded a 3 year Major Project Grant by the Royal Hobart Hospital Research Foundation (2022-24) and leads a team of researchers and clinicians to develop a mobile phone TapTalkTest for quick cognitive screening in clinical and research settings.
